Cite

    Kopylov, U., Avni-Biron, I., Ron, Y., Koslowsky, B., Waterman, M., Daher, S., Ungar, B., Schwartz, D., Zittan, E., Openhaim, M., Yanai, H., Maharshak, N., Bar Gil Shitrit, A., Naftali, T., Eliakim, R., Chowers, Y., Ben-Horin, S., & Dotan, I. (2019). effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease—The Israeli real world experience. Digestive and liver disease, 51(1), 68–74. http://access.bl.uk/ark:/81055/vdc_100076148867.0x00000c